AYTU BIOPHARMA, INC Operating Lease Cost
AYTU BIOPHARMA, INC (AYTU) reported Operating Lease Cost of $339.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-09-22
- AYTU BIOPHARMA, INC operating lease, cost for the quarter ending 2026-06-30 was $85.00K, a 1.19% increase year-over-year.
- AYTU BIOPHARMA, INC operating lease, cost for the quarter ending 2026-03-31 was $85.00K, a 29.17% decline year-over-year.
- AYTU BIOPHARMA, INC operating lease, cost for the quarter ending 2025-06-30 was $84.00K.
- AYTU BIOPHARMA, INC operating lease, cost for the quarter ending 2025-03-31 was $120.00K.
- AYTU BIOPHARMA, INC operating lease, cost for fiscal 2026 was $339.00K, a 27.72% decline from fiscal 2025.
- AYTU BIOPHARMA, INC operating lease, cost for fiscal 2025 was $469.00K.
- AYTU BIOPHARMA, INC operating lease, cost for fiscal 2023 was $1.40M, a 7.93% increase from fiscal 2022.
- AYTU BIOPHARMA, INC operating lease, cost for fiscal 2022 was $1.30M, a 172.90% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $170.00K derived: sum of 2 quarters · filed 2026-09-22 | $339.00K 10-K · filed 2026-09-22 | |
| 2026-03-31 | $85.00K 10-Q · filed 2026-05-13 | $254.00K 10-Q · filed 2026-05-13 | ||
| 2025-06-30 | $84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $204.00K derived: sum of 2 quarters · filed 2026-09-22 | $469.00K 10-K · filed 2026-09-22 | |
| 2025-03-31 | $120.00K 10-Q · filed 2026-05-13 | $385.00K 10-Q · filed 2026-05-13 | ||
| 2023-09-30 | $360.00K 10-Q · filed 2023-11-14 | $686.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.05M derived: sum of 3 quarters · filed 2023-11-14 | $1.41M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | $326.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $686.00K derived: sum of 2 quarters · filed 2023-10-12 | $1.04M derived: sum of 3 quarters · filed 2023-10-12 | $1.40M 10-K · filed 2023-10-12 |
| 2023-03-31 | $360.00K 10-Q · filed 2023-05-11 | $719.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.08M 10-Q · filed 2023-05-11 | $1.30M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-12-31 | $359.00K 10-Q · filed 2023-02-21 | $716.00K 10-Q · filed 2023-02-21 | $938.00K derived: sum of 3 quarters · filed 2023-11-14 | $1.25M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-09-30 | $222.00K 10-Q · filed 2023-11-14 | $579.00K derived: sum of 2 quarters · filed 2023-11-14 | $895.00K derived: sum of 3 quarters · filed 2023-11-14 | $1.23M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $357.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $673.00K derived: sum of 2 quarters · filed 2023-10-12 | $1.00M derived: sum of 3 quarters · filed 2023-10-12 | $1.30M 10-K · filed 2023-10-12 |
| 2022-03-31 | $316.00K 10-Q · filed 2023-05-11 | $646.00K derived: sum of 2 quarters · filed 2023-05-11 | $942.00K 10-Q · filed 2023-05-11 | $1.22M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $330.00K 10-Q · filed 2023-02-21 | $626.00K 10-Q · filed 2023-02-21 | $907.00K derived: sum of 3 quarters · filed 2023-02-21 | $977.00K derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-09-30 | $296.00K 10-Q/A · filed 2023-02-21 | $577.00K derived: sum of 2 quarters · filed 2023-02-21 | $647.00K derived: sum of 3 quarters · filed 2023-02-21 | $677.00K derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $281.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $351.00K derived: sum of 2 quarters · filed 2022-09-27 | $381.00K derived: sum of 3 quarters · filed 2022-09-27 | $476.00K 10-K · filed 2022-09-27 |
| 2021-03-31 | $70.00K 10-Q · filed 2022-05-16 | $100.00K derived: sum of 2 quarters · filed 2022-05-16 | $195.00K 10-Q · filed 2022-05-16 | |
| 2020-12-31 | $30.00K 10-Q · filed 2022-02-14 | $125.00K 10-Q · filed 2022-02-14 | ||
| 2020-09-30 | $95.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |